Pharm GKB summary: Fluoropyrimidine pathways

Pharmacogenetics and Genomics

Volumn 21, Issue 4, 2011, Pages 237-242

  Thorn, Caroline F ^a   Marsh, Sharon ^d   Carrillo, Michelle Whirl ^a   McLeod, Howard L ^c   Klein, Teri E ^a   Altman, Russ B ^a,b  

^a Departments of Bioengineering and Genetics   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c University of North Carolina   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; TEGAFUR; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

DRUG METABOLISM; HUMAN; PHARMACODYNAMICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; ARTICLE; FACTUAL DATABASE; HUMAN GENOME; PHARMACOGENETICS;

ANTIMETABOLITES, ANTINEOPLASTIC; DATABASES, FACTUAL; DEOXYCYTIDINE; FLUOROURACIL; GENOME, HUMAN; HUMANS; PHARMACOGENETICS; TEGAFUR;

EID: 79955477982     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833c6107     Document Type: Review

References (60)

1. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16:215-237. (Pubitemid 19114713)
2. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3:330-338. (Pubitemid 37328853)
3. Hwang JJ, Marshall JL. Capecitabine: fulfilling the promise of oral chemotherapy. Expert Opin Pharmacother 2002; 3:733-743. (Pubitemid 34649703)
4. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-1281. (Pubitemid 28342121)
5. Yen-Revollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res 2008; 14:8-13. (Pubitemid 351377972)
6. Cao D, Russell RL, Zhang D, Leffert JJ, Pizzorno G. Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines. Cancer Res 2002; 62:2313-2317. (Pubitemid 34411710)
7. Van Kuilenburg AB, Meinsma R, Zonnenberg BA, Zoetekouw L, Baas F, Matsuda K, et al. Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res 2003; 9:4363-4367. (Pubitemid 37248392)
8. Kopper L, Lapis K, Institoris L. Incorporation of 3H-dibromodulcitol and 3H-dianhydrodulcitol into ascites tumor cells. Autoradiographic study. Neoplasma 1976; 23:47-52.
9. Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009; 136:187-195.
10. Tsujie M, Nakamori S, Nakahira S, Takahashi Y, Hayashi N, Okami J, et al. Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res 2007; 27:2241-2249. (Pubitemid 47228059)
11. Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N, Yamamoto T. Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol 2005; 57:573-578. (Pubitemid 40562396)
12. Yuan J, Lv H, Peng B,Wang C, Yu Y, He Z. Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol 2009; 63:1103-1110.
13. Yuan JH, Cheng JQ, Jiang LY, Ji WD, Guo LF, Liu JJ, et al. Breast cancer resistance protein expression and 5-fluorouracil resistance. Biomed Environ Sci 2008; 21:290-295.
14. Hagmann W, Jesnowski R, Faissner R, Guo C, Lohr JM. ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology 2009; 9:136-144.
15. Brody JR, Hucl T, Costantino CL, Eshleman JR, Gallmeier E, Zhu H, et al. Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence. Cancer Res 2009; 69:984-991.
16. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer-a tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997; 15:368-381. (Pubitemid 27020595)
17. Humeniuk R, Menon LG, Mishra PJ, Gorlick R, Sowers R, Rode W, et al. Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol Cancer Ther 2009; 8:OF1-OF8.
18. Gmeiner WH. Novel chemical strategies for thymidylate synthase inhibition. Curr Med Chem 2005; 12:191-202. (Pubitemid 40089833)
19. Kunz C, Focke F, Saito Y, Schuermann D, Lettieri T, Selfridge J, et al. Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil. PLoS Biol 2009; 7:e91.
20. Sakamoto E, Tsukioka S, Oie S, Kobunai T, Tsujimoto H, Sakamoto K, et al. Folylpolyglutamate synthase and g-glutamyl hydrolase regulate leucovorinenhanced 5-fluorouracil anticancer activity. Biochem Biophys Res Commun 2008; 365:801-807. (Pubitemid 350234862)
21. Kidd EA, Yu J, Li X, Shannon WD,Watson MA, McLeod HL. Variance in the expression of 5-fluorouracil pathway genes in colorectal cancer. Clin Cancer Res 2005; 11:2612-2619. (Pubitemid 40569461)
22. Iacopetta B, Kawakami K, Watanabe T. Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup? Int J Clin Oncol 2008; 13:498-503.
23. An Q, Robins P, Lindahl T, Barnes DE. 5-Fluorouracil incorporated into DNA is excised by the SMUG1 DNA glycosylase to reduce drug cytotoxicity. Cancer Res 2007; 67:940-945.
24. Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renee N. Dihydropyrimidine dehydrogenase deficiency and fluorouracilrelated toxicity. Br J Cancer 1999; 79:627-630. (Pubitemid 29046246)
25. Van Kuilenburg AB, Vreken P, Abeling NG, Bakker HD, Meinsma R, Van Lenthe H, et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 1999; 104:1-9. (Pubitemid 29134634)
26. Saif MW, Ezzeldin H, Vance K, Sellers S, Diasio RB. DPYD2A mutation: the most common mutation associated with DPD deficiency. Cancer Chemother Pharmacol 2007; 60:503-507. (Pubitemid 47084259)
27. McLeod HL, Collie-Duguid ES, Vreken P, Johnson MR, Wei X, Sapone A, et al. Nomenclature for human DPYD alleles. Pharmacogenetics 1998; 8:455-459. (Pubitemid 29043377)
28. Collie-Duguid ES, Etienne MC, Milano G, McLeod HL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000; 10:217-223. (Pubitemid 30242737)
29. Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26:2131-2138.
30. Marsh S. Thymidylate synthase pharmacogenetics. Invest New Drugs 2005; 23:533-537. (Pubitemid 43162472)
31. Gusella M, Padrini R. G>C SNP of thymidylate synthase with respect to colorectal cancer. Pharmacogenomics 2007; 8:985-996. (Pubitemid 47423688)
32. Marsh S. Impact of pharmacogenomics on clinical practice in oncology. Mol Diagn Ther 2007; 11:79-82. (Pubitemid 46572568)
33. Jensen SA, Vainer B, Witton CJ, Jorgensen JT, Sorensen JB. Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer. Acta Oncol 2008; 47:1054-1061.
34. Afzal S, Jensen SA, Vainer B, Vogel U, Matsen JP, Sorensen JB, et al. MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann Oncol 2009; 20:1660-1666.
35. Terrazzino S, Agostini M, Pucciarelli S, Pasetto LM, Friso ML, Ambrosi A, et al. A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. Pharmacogenet Genomics 2006; 16:817-824. (Pubitemid 44632296)
36. Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidinebased chemotherapy. Clin Cancer Res 2003; 9:1611-1615. (Pubitemid 36554583)
37. Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005; 23: 1365-1369.
38. Marcuello E, Altes A, Menoyo A, Rio ED, Baiget M. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol 2006; 57:835-840.
39. Ruzzo A, Graziano F, Loupakis F, Santini D, Catalano V, Bisonni R, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J 2008; 8:278-288. (Pubitemid 352038307)
40. Capitain O, Boisdron-Celle M, Poirier AL, Abadie-Lacourtoisie S, Morel A, Gamelin E. The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer. Pharmacogenomics J 2008; 8:256-267. (Pubitemid 352038305)
41. Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer 2007; 43:1011-1016. (Pubitemid 46483039)
42. Maitland ML, Vasisht K, Ratain MJ. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci 2006; 27:432-437. (Pubitemid 44051569)
43. De Mattia E, Toffoli G. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation.Eur J Cancer 2009; 45:1333-1351.
44. Wu X, Gu J,Wu TT, Swisher SG, Liao Z, Correa AM, et al. Genetic variationsin radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006; 24:3789-3798. (Pubitemid 46628477)
45. Steiner M, Seule M, Steiner B, Bauer I, Freund M, Köhne CH, et al. 5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case. J Clin Pathol 2005; 58:553-555. (Pubitemid 40646882)
46. Zhang H, Li YM, Jin X. DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients. Med Oncol 2007; 24:251-258. (Pubitemid 350135979)
47. Gross E, Busse B, Riemenschneider M, Neubauer S, Seck K, Klein HG, et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS One 2008; 3:e4003.
48. Huang MY, Fang WY, Lee SC, Cheng TL, Wang JY, Lin SR. ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study. BMC Cancer 2008;8:50.
49. Agostini M, Pasetto LM, Pucciarelli S, Terrazzino S, Ambrosi A, Bedin C, et al. Glutathione S-transferase P1 Ile105Val polymorphism is associated with haematological toxicity in elderly rectal cancer patients receiving preoperative chemoradiotherapy. Drugs Aging 2008; 25:531-539. (Pubitemid 351812260)
50. Etienne MC, Formento JL, Chazal M, Francoual M, Magné N, Formento P, et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 2004; 14:785-792. (Pubitemid 40054334)
51. Zhang W, Press OA, Haiman CA, Yang DY, Gordon MA, Fazzone W, et al. Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer. J Clin Oncol 2007; 25:3726-3731. (Pubitemid 47372614)
52. Huang ZH, Hua D, Li LH, Zhu JD. Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy. J Cancer Res Clin Oncol 2008; 134:1129-1134.
53. Ichikawa W, Takahashi T, Suto K, Sasaki Y, Hirayama R. Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin Cancer Res 2006; 12:3928-3934. (Pubitemid 44078077)
54. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1:65-70. (Pubitemid 33757985)
55. Iacopetta B, Grieu F, Joseph D, Elsaleh H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001; 85:827-830. (Pubitemid 33010548)
56. Kawakami K, Watanabe G. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 2003; 63:6004-6007. (Pubitemid 37187503)
57. Dotor E, Cuatrecases M, Martínez-Iniesta M, Navarro M, Vilardell F, Guinó E, et al. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 2006; 24:1603-1611. (Pubitemid 46638784)
58. Hitre E, Budai B, Adleff V, Czeglédi F, Horváth Z, Gyergyay F, et al. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenet Genomics 2005; 15:723-730. (Pubitemid 41345324)
59. Marcuello E, Alté s A, del Rio E, Cé sar A, Menoyo A, Baiget M. Single nucleotide polymorphism in the 50 tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 2004; 112:733-737. (Pubitemid 39435256)
60. Fernandez-Contreras ME, Sánchez-Hernández JJ, González E, Herráez B, Domínguez I, Lozano M, et al. Combination of polymorphisms within 5' and untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients. Int J Oncol 2009; 34:219-229.